Bluejay Diagnostics, Inc. (BJDX)

USD 2.58

(4.03%)

Market Cap (In USD)

1.42 Million

Revenue (In USD)

-

Net Income (In USD)

-9.95 Million

Avg. Volume

1.08 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.03-1272.0
PE
-0.02
EPS
-114.19
Beta Value
0.728
ISIN
US0956333019
CUSIP
095633103
CIK
1704287
Shares
554012.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Indranil Dey
Employee Count
-
Website
https://www.bluejaydx.com
Ipo Date
2021-11-10
Details
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.